ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation and fireside chat on January 15, 2026 at 12:00 p.m. PT. A live webcast will be available via the Investors section of ALX Oncology’s website under Events and Presentations. A replay of the webcast will be archived and available for up to 90 days after the fireside chat.
Positive
- None.
Negative
- None.
News Market Reaction – ALXO
In the Jan 8 session, ALXO gained 5.08%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.9% during that session. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 07 | Clinical trial results | Positive | +1.4% | Positive Phase 2 lymphoma data for evorpacept with strong response rates. |
| Nov 18 | Investor conferences | Neutral | +4.5% | Announcement of participation in Jefferies and Piper Sandler healthcare conferences. |
| Nov 07 | Earnings and pipeline | Positive | +16.9% | Q3 2025 results, strong ASPEN‑06 biomarker analysis, and cash runway into Q1 2027. |
| Oct 30 | Earnings preview | Positive | -2.5% | Upcoming Q3 results and SITC biomarker data preview for evorpacept. |
| Oct 23 | Clinical trial update | Positive | +8.7% | Preclinical and Phase 1 design data for EGFR‑targeted ADC ALX2004 at oncology meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows generally positive alignment between favorable clinical/earnings updates and share price, with one negative reaction to a conference/earnings scheduling release.
This announcement of a presentation at the 44th J.P. Morgan Healthcare Conference follows several clinically focused and investor-relations events. In Oct–Nov 2025, ALXO highlighted biomarker data, preclinical ADC progress, and then reported Q3 2025 results with cash of $66.5M and funding into Q1 2027, which coincided with a 16.95% gain. Positive Phase 2 lymphoma data at ASH on Dec 7, 2025 also saw a modest uptick. Today’s JPM conference appearance continues a pattern of active engagement with the oncology and investor community.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 15, 2026, at 12:00 p.m. Pacific Time.
The live webcast of the J.P. Morgan fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
